<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72281">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02014142</url>
  </required_header>
  <id_info>
    <org_study_id>PPL GLAU M1</org_study_id>
    <nct_id>NCT02014142</nct_id>
  </id_info>
  <brief_title>Comparison of Latanoprost PPDS With Timolol Maleate GFS in Subjects With Ocular Hypertension or Open-Angle Glaucoma</brief_title>
  <official_title>A Phase 2 Single-Masked, Randomized, Parallel Comparison of the Latanoprost Punctal Plug Delivery System (L-PPDS) With Timolol Maleate Ophthalmic Gel Forming Solution 0.5% in Subjects With Ocular Hypertension or Open-Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mati Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mati Therapeutics Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare efficacy of the latanoprost punctal plug to timolol maleate ophthalmic gel forming
      solution (GFS) 0.5% (administered once every morning). Effect of configuration of L-PPDS
      placement and re-insertion of L-PPDS on efficacy will also be examined.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>IOP change from baseline and the primary analysis time point will be the early morning assessment at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Open-Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Group A. L-PPDS single occlusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Latanoprost Punctal Plug Delivery System (L-PPDS) continuous single occlusion; L-PPDS will be inserted in the lower punctum and no plug will be inserted in the upper punctum of each eye; L-PPDS will remain for a period of 14 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B. L-PPDS double occlusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Latanoprost Punctal Plug Delivery System (L-PPDS) continuous double occlusion; L-PPDS will be inserted in the lower punctum and non-therapeutic (NT) plug will be inserted in the upper punctum of each eye and both will remain for a period of 14 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C. L-PPDS re-insertion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Latanoprost Punctal Plug Delivery System (L-PPDS) re-insertion; L-PPDS will be inserted in the lower punctum and non-therapeutic (NT) plug will be inserted in the upper punctum of each eye; The L-PPDS will remain for a period of 12 weeks. At Week 12, after the final intraocular pressure (IOP) measurement, the L-PPDS will be replaced and will remain for two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D. Timolol Maleate GFS, 0.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Timolol Maleate GFS drops; One drop timolol maleate ophthalmic GFS 0.5% QAM for 14 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost Punctal Plug Delivery System (L-PPDS)</intervention_name>
    <description>Latanoprost Punctal Plug Delivery System (L-PPDS)</description>
    <arm_group_label>Group A. L-PPDS single occlusion</arm_group_label>
    <arm_group_label>Group B. L-PPDS double occlusion</arm_group_label>
    <arm_group_label>Group C. L-PPDS re-insertion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol Maleate GFS, 0.5%</intervention_name>
    <description>Timolol Maleate GFS, 0.5%</description>
    <arm_group_label>Group D. Timolol Maleate GFS, 0.5%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 18 years or older at the time of the screening examination

          2. Subject diagnosed with bilateral OAG or OH

          3. Subject IOP is currently controlled (&lt; 21 mmHg) with a topical prostaglandin or in
             conjunction with one other topical ocular hypotensive drug, not including any
             fixed-combination formulations (i.e., Cosopt, Combigan, Azarga, etc.) for at least
             one month or more

          4. Subject who has lower and upper puncta &gt; 0.5 mm and &lt; 0.9 mm (pre-dilation) in both
             eyes

          5. Subject must be able and willing to read, comprehend and give Authorization for
             Use/Disclosure of Health Information (HIPAA) and informed consent

          6. Subject must be willing to comply with study instructions, dosing (if applicable),
             agree to make all office appointments, and complete the entire course of the study

          7. Women of child-bearing potential must not be pregnant or lactating, must have a
             negative pregnancy test at screening and must be practicing an adequate method of
             birth control, including intrauterine device (IUD); oral, dermal (&quot;patch&quot;), implant
             or injected contraceptives; tubal ligation; or barrier methods with spermicide

          8. Subject has a central corneal thickness of &gt; 500 μm and &lt; 600 μm in study eye

          9. Subject has a BCVA or pinhole visual acuity (Snellen) of 20/100 or better in both
             eyes

        Exclusion Criteria:

          1. Subject with a history of non-response to topical prostaglandin eye drops for OAG/OH

          2. Subject with angle-closure glaucoma, neovascular glaucoma, traumatic glaucoma or
             iridocorneal endothelium syndrome in either eye

          3. Subject with a known sensitivity to latanoprost, timolol, fluorescein, topical
             anesthetic, silicone, any inactive ingredient of the L-PPDS or any other products
             required for the study procedures

          4. Subject with a history of intolerance to topical beta-blocker therapy

          5. Subject with &gt; 0.8 vertical cup or completely notched optic nerve head rim in either
             eye

          6. Subject with any functionally significant visual field loss or progressive field loss
             within the last year in either eye

          7. Subject with a history of complications, AEs, trauma or disease in the nasolacrimal
             area, whether or not it was due to punctal plug wear, including but not limited to
             dacryocystitis, inflammation or canaliculitis in study eye

          8. Subject with structural lid abnormalities (i.e., ectropion, entropion) in study eye

          9. Subject with an active lid disease in either eye (i.e., moderate or severe
             blepharitis, meibomianitis) that requires medical treatment

         10. Subject with a history of chronic/recurrent inflammatory eye disease (i.e.,
             scleritis, uveitis, herpes keratitis) in either eye

         11. Subject who would require the use of any ocular topical medication(s), an over-the
             counter drop(s), ointment(s) or gel(s), other than the study ocular hypotensive
             medication(s) in either eye during the study period

         12. Subject who has had any ophthalmic surgical procedures (i.e., glaucoma laser,
             minimally invasive glaucoma surgery, cataract, refractive, etc.) in study eye within
             the last six months or will require ophthalmic surgery before completing the study

         13. Subject with a history of penetrating keratoplasty in study eye

         14. Subject who is incapable of instilling ocular drops into his or her eyes

         15. Subject requiring the use of a contact lens in either eye at any time during the
             study period

         16. Subject with advanced diabetic retinopathy, branch retinal vein occlusion or central
             retinal vein occlusion in either eye

         17. Subject with a history of macular edema in either eye

         18. Subject currently on any systemic medication [i.e., beta-blocker, carbonic anhydrase
             inhibitors, corticosteroids (including dermal), etc.], that may have an effect on the
             subject's IOP, or who will require its use during the study period (Note: an inhaled
             steroid, systemic beta-blocker or β-adrenoceptor antagonist may be permitted,
             providing the subject has maintained a stable dosage regimen for at least the last
             three months)

         19. Subject contraindicated to therapy with a beta-blocker (i.e., history or presence of
             bradycardia, untreated congestive heart failure, untreated second- or third-degree
             heart block, sino-atrial block, myasthenia gravis, cardiogenic shock, history or
             presence of bronchial asthma, bronchial hyperreactivity, severe chronic obstructive
             pulmonary disease, or history of bronchospasm)

         20. Subject with an uncontrolled systemic disease or a medical condition that may
             increase the risk associated with study participation or administration of study
             treatment or that may interfere with the interpretation of study results (e.g.,
             autoimmune disease if the subject is on chronic medications and has ocular
             involvement; host-versus-graft disease)

         21. Subject currently participating or has participated within the last 30 days prior to
             the start of this study in a drug, device or other investigational research study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Brittany Brown</last_name>
    <phone>701-483-3599</phone>
    <phone_ext>105</phone_ext>
    <email>brittanybrown@trialrunners.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bob Butchofsky</last_name>
    <email>bbutchofsky@matitherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wolstan &amp; Goldberg Eye Associates</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien F. Goldberg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana Universtiy - Eugene and Marilyn Glick Eye Institute Ophthalmology Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darrell WuDunn, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Holland, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Vision Institute</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55420</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Y. Ralph Chu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Associates</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregg Berdy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Eye Care, Ltd.</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael S. Korenfeld, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abrams Eye Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jack Abrams, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Long Island</name>
      <address>
        <city>Lynbrook</city>
        <state>New York</state>
        <zip>11563</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald M. Caronia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Steven T. Simmons</name>
      <address>
        <city>Slingerlands</city>
        <state>New York</state>
        <zip>12159</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven T. Simmons, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Philadelphia Eye Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Repke, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wills Eye Hospital</name>
      <address>
        <city>Phildelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L. Jay Katz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Eye Surgeons</name>
      <address>
        <city>Maryville</city>
        <state>Tennessee</state>
        <zip>37803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth W. Olander, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Total Eye Care</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugene B. McLaurin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rashid, Rice &amp; Flynn</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Flynn, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 4, 2014</lastchanged_date>
  <firstreceived_date>December 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
